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Abstract
RNA helicases represent a large family of proteins implicated in many biological processes including ribosome biogenesis,
splicing, translation and mRNA degradation. However, these proteins have little substrate specificity, making inhibition of
selected helicases a challenging problem. The prototypical DEAD box RNA helicase, eIF4A, works in conjunction with other
translation factors to prepare mRNA templates for ribosome recruitment during translation initiation. Herein, we provide
insight into the selectivity of a small molecule inhibitor of eIF4A, hippuristanol. This coral-derived natural product binds to
amino acids adjacent to, and overlapping with, two conserved motifs present in the carboxy-terminal domain of eIF4A.
Mutagenesis of amino acids within this region allowed us to alter the hippuristanol-sensitivity of eIF4A and undertake
structure/function studies. Our results provide an understanding into how selective targeting of RNA helicases for
pharmacological intervention can be achieved.
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Introduction
Helicases and translocases are classified into 6 superfamilies (SF1–
SF6) based on the arrangement of conserved sequence motifs, with
many providing essential functions in nucleic acid metabolic
processes [1]. Members of the SF2 family consist of RNA helicases
implicated in transcription, RNA export, splicing, translation,
ribosome biogenesis, miRNA processing, and RNA decay [2–4].
Eukaryotic initiation factor (eIF) 4A is one of the archetypical
founding members of the DEAD box helicase family, the largest
subclass of the SF2 family. eIF4A is an abundant translation factor
thatexistsinfreeform(referred to hereinaseIF4Af)orasasubunitof
the heterotrimeric cap binding complex, eIF4F (referred to herein as
eIF4Ac) [5,6]. It participates in the ribosome recruitment phase of
translationand isdelivered tothe cap structure(m7GpppN,whereN
is any nucleotide) of mRNA templates as a subunit of eIF4F. It is
thought to prepare the mRNA template for 43S pre-initiation
complex (40S ribosome and associated factors) binding by
unwinding local secondary structure. The helicase activity of eIF4Ac
is ,20-fold more efficient than eIF4Af [7,8] and during initiation
eIF4Af is thought to cycle through the eIF4F complex [9–12]. There
are two highly related isoforms, eIF4AI and eIF4AII (85–90%
sequence identity) which are thought to be functionally interchange-
able for translation initiation [12,13]. A third protein, called
eIF4AIII (DDX48), has ,65% sequence identity to eIF4AI and is
part of the exon junction complex that participates in nonsense
mediated decay [14,15]. The helicase activity of eIF4A is inhibited
when associated with the tumor suppressor gene product, Pdcd4, an
event that is regulated by the mammalian target of rapamycin
(mTOR) [16,17]. This underscores an important link between
cellular homeostasis and translational control at the level of eIF4A
availability.
In a screen aimed at identifying novel inhibitors of translation
initiation, we identified and characterized two marine-derived
natural products, pateamine and hippuristanol, that modulate
eIF4A activity [18–20]. The binding site of pateamine on eIF4A is
not defined, although its activity is dependent on the nature of the
linker region joining the amino-terminal (NTD) and carboxy-
terminal domains (CTD), a region with significant sequence
variation among DEAD-box family members [21]. On the other
hand, hippuristanol interacts with eIF4AI-CTD (residues 237–406)
and blocksthe RNA-dependent ATPase, RNAbinding,and helicase
activitiesofeIF4AI[20].Herein,wedefinethehippuristanol-binding
site on eIF4A. The site displays extensive sequence variation among
DEAD box RNA helicases and provides a framework for
understanding the selectivity of hippuristanol. We utilize this
information to generate eIF4A alleles with reduced sensitivity to
this small molecule and capable of rescuing hippuristanol-induced
inhibition of translation. This allowed us to probe structure-function
relationships of eIF4A in translation.
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Defining the eIF4A hippuristanol binding site
To identify the amino acids involved in hippuristanol binding, a
series of NMR experiments were undertaken in which
1H-
15N-
HSQC spectra of uniformly labelled eIF4AI-CTD were obtained
in the absence or presence of compound (Fig. 1A). Residues that
experienced significant chemical shift changes (.mean plus
standard deviation) are indicated in grey whereas those displaying
direct NOE contacts (,5A ˚) are highlighted in yellow (Fig. 1B).
Hippuristanol binds directly (exhibits NOEs) to the N-terminal
ends of b-strands E5 and E6, the C-terminal end of helix H4, as
well as the loop regions adjacent to these secondary structural
elements (Figs. 1A–C). Furthermore, adjacent regions undergo
significant chemical shift changes (Fig. 1C; highlighted in blue).
We analyzed the position of the hippuristanol binding site in the
context of a model based on the domain orientation of eIF4AIII in
the exon junction complex (EJC) (PDB code 2HYI) [22,23]
(Fig. 1D). Here, the eIF4AI NTD crystal structure (PDB #2G9N)
was used and the eIF4AIII-CTD was replaced with the homology
model for eIF4AI [24]. The positions of the RNA and ADPNP are
taken from the EJC [22]. Accordingly, the hippuristanol-binding
site on the eIF4AI-CTD is directly adjacent to the ATP-binding
site in the NTD. Since hippuristanol does not inhibit ATP
crosslinking to eIF4A [20], it may perturb the interface between
the NTD and CTD domains. The hippuristanol-binding site is far
from the RNA-binding face and allows us to conclude that
hippuristanol inhibits eIF4A RNA binding in an allosteric manner.
Selectivity of hippuristanol for eIF4A
With the exception of R247
eIF4AI and T328
eIF4AI/II, all the
hippuristanol binding residues are present in murine eIF4AI,
eIF4AII, and the yeast eIF4A homolog Tif1/2p (Fig. S1). This
hippuristanol binding site however is not conserved in eIF4AIII and
we note 7 amino acid differences (Fig. S1; R247
eIF4AI is changed to
K252
eIF4AIII,T 3 2 8
eIF4AI to S333
eIF4AIII,L 3 3 1
eIF4AI to V336
eIF4AIII,
L332
eIF4AI to W337
eIF4AIII,I 3 3 6
eIF4AI to L341
eIF4AIII, Q339
eIF4AI to
P344
eIF4AIII, and V344
eIF4AI to I349
eIF4AIII). Among the residues
that differ between eIF4AI and eIF4AIII, the L341
eIF4AIII ,
P344
eIF4AIII and I349
eIF4AIII changes are expected to directly impact
onhippuristanolbindingsincethecorrespondingsidechainsarepart
of the binding pocket (Fig. S1). The side chains of the other
substitutions do not point towards the binding site and are not
expected to impact on hippuristanol affinity.
We compared the relative sensitivities of murine eIF4AI, murine
eIF4AII, and human eIF4AIII to hippuristanol in an RNA-
dependent ATPase assay (Fig. 2A). eIF4AI and eIF4AII showed
similar sensitivities to hippuristanol, whereas eIF4AIII required
,10-fold higher concentrations of compound to achieve equiva-
lent inhibition (Fig. 2A). Tif1/2p ATPase activity displayed a
similar sensitivity to hippuristanol as eIF4AI/II (data not shown),
consistent with the conserved nature of the amino acids flanking
motifs V and VI (Fig. S1). Consistent with these results, 10 mM
hippuristanol inhibited RNA binding of eIF4AI, but not eIF4AIII
(Fig. 2B, compare lane 2 to 1 and lane 4 to 3).
Alignment of the region encompassing the hippuristanol
binding site of murine (Fig. S2A) and human (Fig. S2B) DEAD
box helicases indicates extensive sequence variation. Human
DDX52 has a very high degree of conservation with eIF4AI in the
hippuristanol binding region, with two changes present among the
amino acids showing direct NOE contacts (Fig. S2B). Eleven of 17
amino acids (from regions encompassing motifs V and VI) showing
weaker NOEs are also present in hDDX52 (Fig. S2B). hDDX19
contains five of the eight amino acids showing direct NOE
contacts and 11 of the 17 amino acids showing weaker NOEs (Fig.
S2B). Hippuristanol did not inhibit the RNA binding properties of
hDDX19 (Fig. 2B) nor the ATPase activity of hDDX52 or
hDDX19 (Fig. 2C). These results provide insight into why
hippuristanol is selective for eIF4A since the amino acids that
define the hippuristanol binding site are not well conserved among
other DDX family members.
Modulating eIF4A Hippuristanol Sensitivity
Using the mapping information from these NMR studies, we
addressed the feasibility of modulating hippuristanol sensitivity
among eIF4A family members (Fig. S1). Given that Ded1p is
resistant to inhibition by hippuristanol (Hipp
R), we used
information obtained from the sequence comparison of the
hippuristanol binding site to guide us in our mutagenesis approach
[20] (Fig. S1). The
338VQ
339 eIF4AI amino acid pair immediately
downstream of motif V in eIF4A was altered to
338IP
339 (present in
Ded1p) or
338IG
339 (for future NMR studies; since proline residues
do not have amide protons and are not visible in
1H-
15N HSQC
spectra). These mutants also harboured a G363T alteration in
motif VI (eIF4AI
IG/T), so we generated mutants harbouring only
either a G363T or a
338VQ
339 to
338IG
339 alteration (Fig. S1;
eIF4AI
IG and eIF4AI
T). IP/T variants of eIF4AII and eIF4AIII
were also generated (Fig. S1). We also addressed whether we could
increase the sensitivity of eIF4AIII to hippuristanol by rebuilding a
complete hippursitanol site (Fig. S1; eIF4AIII
TLLQV).
eIF4AI
IG/T and eIF4AI
IP/T are more active than eIF4AI in an
RNA-dependent ATPase assay (Fig. 3A and data not shown). The
increased ATPase activity was principally a consequence of the
338VQ
339 to
338IG
339 alteration (Fig. S3). Hippuristanol inhibited
eIF4AI ATPase activity but had little effect on the ATPase activity
of eIF4AI
IG/T and eIF4AI
IP/T (Fig. 3A and B). Similarly, eIF4AII
was sensitive to inhibition by hippuristanol whereas eIF4AII
IP/T
was not (Fig. 3B). Titration of hippuristanol revealed that the
ATPase activity of eIF4AIII
IP/T was resistant to hippuristanol at
concentrations up to 75 mM with a slight inhibition of activity at
100 mM (Fig. 3C). In contrast, eIF4AIII
TLLQV was more sensitive
to hippuristanol than eIF4AIII (Fig. 3C), showing a dose-response
profile that resembled that of eIF4AI and eIF4AII (Fig. 2A). We
further characterized the eIF4AI and eIF4AII hippuristanol-
resistant alleles in RNA binding and helicase assays. As expected,
hippuristanol reduced the ability of eIF4AI and eIF4AII to interact
with RNA (Fig. S4A, compare lanes 2 and 8 to 1 and 7,
respectively) but did not affect the RNA binding activities of
eIF4AI
IG/T, eIF4AI
IP/T, and eIF4AII
IP/T (Fig. S4A, compare
lanes 4, 6, and 10 to 3, 5, and 9, respectively). The helicase activity
of eIF4AI and eIF4AII is blocked by hippuristanol, whereas both
eIF4AI
IG/T and eIF4AII
IP/T are resistant to inhibition (Fig. S4B).
Taken together, these results demonstrate the feasibility of
generating mutant alleles of DEAD-box helicase members with
increased or reduced sensitivity to hippuristanol. This provides a
powerful means by which to investigate the function of individual
members of this family of proteins.
Structure/Function Studies of eIF4A
We used the ability to generate hippuristanol-resistant alleles of
eIF4A to probe structure-function relationships in vitro. Specifical-
ly, we asked: (i) if the helicase activity of eIF4AI is required for
translation (or is its ATPase activity sufficient); (ii) if eIF4A:eIF4G
interaction is essential for translation, and (iii) whether eIF4AI and
eIF4AII are functionally interchangeable. The design of a helicase
deficient mutant of eIF4A, eIF4AI
Hel/IG/T, was guided by a
previously described Vasa mutation in which this alteration
abolished helicase activity but only reduced ATPase activity by
50% (Fig. S1) [25]. eIF4AI
Quad/IG/T contains 4 missense
Hippuristanol Binding to eIF4A
PLoS ONE | www.plosone.org 2 February 2008 | Volume 3 | Issue 2 | e1583Figure 1. Hippuristanol binds to eIF4AI-CTD. (A) Chemical shift changes of
1H-
15N-HSQC peaks, (Dd(
1H)+0.2 Dd(
15N), of eIF4A-I-CTD (52 mM)
upon addition of hippuristanol (100 mM). Free and bound forms are in slow exchange and the resonances of eIF4AI-CTD had to be assigned in both
states. The locations of secondary structures were identified by NMR and are indicated with magenta arrows (b-strands) and yellow rectangles
(helices). (B) Primary amino acid sequence of eIF4AI indicating residues involved in hippuristanol binding. NOEs are highlighted in yellow, whereas
those within 5A ˚ are in grey and correspond to regions a, b, and c in A. Residues in bold denote conserved amino acids that define motifs V (ARGID)
and VI (HRIGRGGRFG) of DEAD box family members [40]. Arrows denote residues identified in Vasa that interact with ATP (red), RNA (blue), or are
involved in interdomain interaction (green)[25]. (C) Surface and ribbon representations of the model for eIF4AI-CTD. The CTD is viewed from the
position of the NTD. Residues of eIF4AI-CTD that show NOEs to hippuristanol are coloured yellow, those exhibiting major chemical shift changes but
no NOEs are coloured blue. Residues contacting eIF4G are in red [24]. The b-sheets (E1–E6) and a-helices (H1–H6) are labelled and refer to the
locations marked in A. RNA and ADPNP are shown as sticks models. (D) Location of the hippuristanol-binding site in a model for eIF4AI complexed
with RNA and ADPNP. The model is composed of the crystal structure of human eIF4AI-NTD (PDB #2G9N) and the homology model of the eIF4AI-
CTD [24]. The two domains are aligned to the structure of eIF4AIII from the EJC from which the RNA and ADPNP binding sites are adapted (PDB#
2HYI) [22]. Color scheme of amino acid residues is as in C.
doi:10.1371/journal.pone.0001583.g001
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eIF4AI
Hel/IG/T showed a reduction in the rate of RNA-dependent
ATP hydrolysis compared to eIF4AI
IG/T - bringing it to levels
similar to wild-type eIF4AI (Fig. S5A). As expected, eIF4AI
Hel/IG/T
does not display helicase activity (Fig. S5B, compare lanes 5 to 3),
and its RNA binding activity is resistant to hippuristanol (Fig. S5C).
eIF4AI
Quad/IG/T has a similar rate of RNA-dependent ATP
hydrolysis as eIF4AI
IG/T (Fig. S5A), possesses helicase activity
(Fig. S5D), and its RNA binding activity is resistant to hippuristanol
(Fig. S5C). As predicted, it is impaired in its ability to interact with
eIF4GI (Fig. S6).
We tested whether the Hipp
R eIF4A alleles could rescue
translation when this process is inhibited with hippuristanol (Fig. 4).
In vitro translations were performed in rabbit reticulocyte lysate
(RRL) programmed with the bicistronic reporter mRNA FF/
HCV/Ren (Fig. 4A) [20]. Here, Renilla (Ren) luciferase expression
is HCV-driven and not eIF4A-dependent [20], thus serving as an
internal control. Firefly (FF) luciferase expression is inhibited by
.90% in the presence of 5 mM hippuristanol, whereas that of
Renilla is slightly reduced (Fig. 4B, compare lane 2 to 1). Renilla
luciferase RLU readings from the translation products of this
experiment are consistent with a 2-fold reduction in activity (LL,
data not shown). Addition of wild-type eIF4AI does not rescue the
inhibition by hippuristanol, whereas eIF4AI
IG/T restored transla-
tion to ,60% of normal levels (Fig. 4B, compare lanes 6 and 4 to 5
and 3, respectively). These results are consistent with the idea that
inhibition of translation by hippuristanol in vitro is a direct
consequence of impaired eIF4A activity. Neither eIF4AI
Quad/IG/T
or eIF4AI
Hel/IG/T are able to rescue translation inhibition by
hippuristanol (Fig. 4B) indicating that eIF4A’s helicase activity and
its ability to interact with eIF4G are necessary for its role in
translation.
Next, we tested if eIF4AI and eIF4AII are functionally
redundant for translation. To this end, we assessed the ability of
eIF4AI
IP/T and eIF4AII
IP/T to rescue hippuristanol-induced
translation inhibition (Fig 4C). Like eIF4AI
IG/T (Fig. 4B), both
eIF4AI
IP/T and eIF4AII
IP/T rescued to the same extent (Fig. 4C,
compare lanes 10 and 6 to 8 and 4, respectively). The rescue by the
Hipp
R mutants in these experiments was specific for hippuristanol,
since it was not observed when translation was inhibited by
pateamine - another eIF4A small molecule activity modulator
(Fig. 4D, compare lane 9 to 8).
Hippuristanol targets eIF4A in vivo
We used a genetic approach to demonstrate that hippuristanol
targets eIF4A in vivo. S. cerevisiae contains two eIF4A orthologues of
identical amino acid sequence, called Tif1 and Tif2 [26]. We first
assessed whether hippuristanol can block translation in an in vitro S.
cerevisiae system programmed with Renilla mRNA (Fig. 5A).
Concentrations of 1 mM hippuristanol were sufficient to inhibit
protein synthesis (Fig. 5A). If Tif1/2p is the relevant biological
target of hippuristanol in vivo, then Saccharomyces cerevisiae strains
showing reduced activity of Tif1/2p should be more sensitive to
growth inhibition by this compound than the wild-type (wt) strain
[26]. The growth of 4A-ts, which contains the temperature
sensitive V69S allele of Tif1p, was more sensitive than the wild-
type parental strain or strains containing a deletion of Tif1p (Dtif1)
or Tif2p (Dtif2) (Figs. 5B–C). These results imply that hippur-
istanol targets the yeast homologue of eIF4A (Tif1/2p) in vivo to
affect growth.
These findings prompted us to use the Xenopus laevis translation
system to assess if hippuristanol-induced inhibition of translation
could be relieved by eIF4AI
IG/T in vivo (Fig. 6). The hippuristanol
binding site is 100% conserved between the murine and X. laevis
eIF4AI proteins (data not shown). Addition of 5 mM hippuristanol
inhibited cap-dependent translation of injected FF/HCV/Ren
mRNA by 95% (Fig. 6A). Co-injection of recombinant eIF4AI
slightly relieved the inhibition by hippuristanol to 30% of vehicle
treated cells, whereas introduction of eIF4AI
IG/T completely
rescued the effect (Fig. 6A). Equivalent amounts of recombinant
eIF4AI and eIF4AI
IG/T were delivered to the cells upon micro-
injection, as assessed by western blot analysis of extracts prepared
from the injected eggs (Fig. 6B).
Discussion
Herein, we demonstrate that hippuristanol interacts with amino
acids within and adjacent to motifs V and VI of eIF4AI, two
regions implicated in RNA, ATP, and interdomain contacts
[23,25]. Hippuristanol inhibits the RNA-dependent ATPase
activity and RNA binding ability of eIF4A, but does not prevent
binding of ATP to eIF4A [20]. The hippuristanol-binding site on
Figure 2. Selectivity of hippuristanol for eIF4A. (A) Inhibition of
eIF4A RNA-dependent ATPase activity by hippuristanol. ATPase assays
were performed with 0.1 mg of His6-eIF4AI or His6-eIF4AII at 25uCo r
with 0.1 mg of His6-eIF4AIII at 37uC for 2 h with 0.1 mCi c-
32P-ATP (10 Ci/
mmol). Following analysis by TLC and quantitation using a Fuji BAS
2000 phosphoimager, the percent hydrolysis was determined and set
relative to the DMSO vehicle control reactions. Each value represents
the average of three measurements with the error shown as the
standard deviation. (B) Crosslinking of recombinant proteins to RNA in
the presence of hippuristanol.
32P-labelled CAT RNA was cross-linked to
0.5–1 mg of the indicated recombinant protein in the presence or
absence of hippuristanol, separated by SDS-PAGE, and visualized by
autoradiography. [Note that in our hands, recombinant hDDX52 did not
crosslink to RNA.] (C) Relative ATPase activity of eIF4AI, hDDX19, and
hDDX52 in the presence of 50 mM hippuristanol. eIF4AI and hDDX19
where performed at 25uC for 5 minutes while hDDX52 was incubated
for 60 minutes to allow for analysis to be in the linear range of ATP
hydrolysis. The percent ATP hydrolysis was determined in the presence
of hippuristanol and set relative to the DMSO vehicle control reactions.
The results represent the average of 3 experiments with error bars
signifying the standard deviation.
doi:10.1371/journal.pone.0001583.g002
Hippuristanol Binding to eIF4A
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ATP-interacting surfaces. Since hippuristanol does not bind to the
NTD, ATP would still be able to bind to eIF4A-NTD (its main
binding site) in the presence of hippuristanol. The amino acid
corresponding to Thr
329 of eIF4AI (Fig. S1) in Vasa and eIF4AIII
is implicated in RNA binding via interaction with a phosphate
residue on the RNA backbone. We therefore speculate that either:
(i) hippuristanol interferes with proper interdomain interaction,
which in turn abolishes RNA binding or (ii) affects alignment of
Thr
329 with its target phosphate on RNA. We favor the former
possibility as this mechanism of action has been documented by
Nakamura and colleagues, who identified an RNA aptamer that
inhibits eIF4A activity by also interfering with interdomain
interaction [27].
Our results extend previous studies implicating eIF4A’s helicase
activity and eIF4A:eIF4G interaction as being essential for
translation (Fig. 4). eIF4AI
IG/T, but not eIF4AI
Quad/IG/T, was
capable of rescuing hippuristanol-induced translation inhibition
(Fig. 4), implying that eIF4AI
IG/T can assemble into the eIF4F
complex and does not rescue translation as a free subunit.
Consistent with this interpretation, rescue of translation by
eIF4AI
IG/T is inhibited by the cap analog (m
7GDP) (data not
shown). Although eIF4A plays an accessory role in promoting 48S
complex formation on unstructured mRNA templates, it is
required for 48S complex formation and translation of mRNAs
containing weakly structured (213.6 kcal/mol) hairpins [28].
eIF4A has been proposed to cycle through the eIF4F complex
during initiation [12] and mutants of eIF4A have been previously
described which appear to act in a dominant-negative manner to
trap eIF4F in an inactive state, thus inhibiting translation [10,11].
The inverse relationship between 59 secondary structure and
sensitivity to inhibition by a dominant-negative mutant of eIF4A
[11] is consistent with the idea that eIF4A functions to unwind
secondary structure in the 59 UTR during initiation to create a
ribosome landing pad. However, not all potential activities of
DEAD box proteins are necessarily involved in their function.
Case in point is eIF4AIII where ATP hydrolysis is not required for
its participation in NMD [29]. Therefore, we directly tested the
requirement for eIF4A’s helicase activity in translation using a
hippuristanol-resistant helicase-defective mutant and found it to be
essential for eIF4A’s participation in initiation (Fig. 4). We also
find that eIF4AI and eIF4AII are interchangeable in their ability
Figure 3. Characterization of eIF4A hippuristanol-resistant mutants. (A) Consequence of mutations in the eIF4AI hippuristanol binding site
on ATP hydrolysis. ATP hydrolysis was monitored using 1 mg His6-eIF4AI or His6-eIF4AI
IG/T in the presence or absence of 10 mM hippuristanol. Each
value represents the average of three measurements with the standard deviation presented. (B) Relative ATPase activity of eIF4A mutants in the
presence of hippuristanol. The percent ATP hydrolysis was determined in the presence of hippuristanol and set relative to the values obtained in the
presence of control reactions containing vehicle (DMSO). The results represent the average of 3–7 experiments with error bars signifying the standard
deviation. (C) Altered hippuristanol sensitivity of eIF4AIII. ATPase assays were performed with 0.5 mg recombinant protein with 0.1 mCi c-
32P-ATP
(10 Ci/mmol). Following analysis by TLC and quantitation using a Fuji BAS 2000 phosphoimager, the percent hydrolysis was determined and set
relative to the DMSO vehicle control reactions. Each value represents the average of three measurements with the standard deviation shown.
doi:10.1371/journal.pone.0001583.g003
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PLoS ONE | www.plosone.org 5 February 2008 | Volume 3 | Issue 2 | e1583Figure 4. Functional requirements for eIF4A activity in translation. (A) Schematic representation of the reporter construct used in these
studies is shown on top. (B) Left Panel: Rescue of hippuristanol-induced translation inhibition by eIF4AI
IG/T. In vitro translations in RRL programmed
with capped FF/HCV/Ren mRNA (8 mg/ml) and containing vehicle (0.1% DMSO) or 5 mM hippuristanol (in 0.1% DMSO) were supplemented with
0.5 mg recombinant protein. Protein synthesis was assessed by using
35S-methionine incorporation as well as by monitoring luciferase assays. Protein
products were separated by SDS-PAGE and visualized by autoradiography. The arrow indicates the position of migration of the firefly luciferase,
whereas the arrowhead denotes the position of migration of Renilla luciferase. Right panel: Relative luciferase activity obtained in the presence of
recombinant eIF4A. Firefly RLU readings obtained in the presence of recombinant eIF4A and hippuristanol were standardized to Renilla RLU values
and set relative to the values obtained in the presence of vehicle (DMSO). The average of 3–8 experiments is shown with the standard deviations
denoted. (C) eIF4AI and eIF4AII are functionally interchangeable. In vitro translations in RRL containing vehicle (DMSO) or 5 mM hippuristanol were
supplemented with 0.8 mg recombinant eIF4A where indicated, and programmed with capped FF/HCV/Ren mRNA (8 mg/ml). Left panel: Protein
products were separated by SDS-PAGE and visualized by autoradiography. The arrow indicates the position of migration of the firefly luciferase,
whereas the arrowhead denotes the position of migration of Renilla luciferase. Right panel: Relative luciferase activity obtained in the presence of
recombinant eIF4A and hippuristanol was standardized to Renilla Luciferase levels and set relative to the values obtained in the presence of vehicle
(DMSO). The average of 4–5 experiments is shown with the standard deviations denoted. (D) Translational rescue by eIF4AI
IG/T is selective for
hippuristanol. In vitro translations in RRL containing vehicle (DMSO), 5 mM hippuristanaol, or 0.4 mM pateamine were supplemented with 0.8 mg
recombinant eIF4A where indicated, and programmed with capped FF/HCV/Ren mRNA (8 mg/ml). Protein products were separated by SDS-PAGE and
visualized by autoradiography. The arrow indicates the position of migration of the firefly luciferase, whereas the arrowhead denotes the position of
migration of Renilla luciferase. The figure is a representative display of one of two experiments.
doi:10.1371/journal.pone.0001583.g004
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PLoS ONE | www.plosone.org 6 February 2008 | Volume 3 | Issue 2 | e1583Figure 6. In vivo rescue of hippuristanol-induced translation inhibition by eIF4AI
IG/T. (A) Rescue of translation in Xenopus oocytes by
eIF4AI
IG/T. The percent rescue was determined by normalizing the Firefly luciferase values to Renilla luciferase [to standardize for small variations in
sample injection volumes], followed by dividing by the ratio obtained from the vehicle-treated samples (which was set at 100%). The data presented
is the average of 9 independent sets of injections with the standard deviations denoted. (B) Western blot of extracts prepared from oocyte extracts.
The equivalent of one oocyte was separated on a 10% SDS-PAGE, transferred to Immobilon-P, and probed with a-His6 (to detect recombinant His6-
eIF4AI) or a-tubulin antibodies.
doi:10.1371/journal.pone.0001583.g006
Figure 5. Hippuristanol targets eIF4A in vivo. (A) Inhibition of Renilla luciferase reporter in a yeast in vitro translation extract. Hippuristanol was
added to a S. cerevisiae cytosolic translation extract programmed with 0.12 mg/ml capped Renilla luciferase mRNA. At various points following
initiation of the translation reaction, aliquots were removed and the relative luciferase units (RLU) determined. (B) Haploinsufficiency for Tif1/2p leads
to increased sensitivity to hippuristanol in vivo. Haploid wild type cells (strain CWO4) or an isogenic strain carrying the temperature-sensitive tif1V79A
allele (strain SS13-3A/pSSC120) [41] were cultivated in rich medium (YPD) at 27uC to an O.D.600 of 0.2, at which point hippuristanol (1 mMo r1 0mM
final concentration) or solvent (DMSO, 0.1%) was added and the growth of different cultures was monitored for several hours by measuring the
O.D.600.( C) Serial dilutions of different haploid yeast strains were plated on YPD-plates containing the indicated concentrations of hippuristanol and
incubated for 2–3 days at 27uC: wt (CWO4), wild type strain CWO4; 4A-ts, strain SS13-3A/pSSC120 carrying the tif1V79A allele; Dtif1, a BY4741-
derivative strain carrying a tif1::kanX deletion; Dtif2, a BY4741-derivative strain carrying a tif2::kanX deletion; wt (BY4741), wild type strain BY4741.
doi:10.1371/journal.pone.0001583.g005
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both eIF4AI and eIF4AII can associate with the eIF4F complex
[12,13], and our studies extend these results by demonstrating that
an eIF4A mutant lacking this function cannot participate in the
translation process. The ability to generate hippuristanol-sensitive
alleles of various DDX family members is a powerful tool with
which to assign function and undertake structure-function studies.
Materials and Methods
NMR Spectroscopy and modeling
NMR spectra were recorded at 298 K on a Varian Inova 600
and Inova 500 instruments equipped with cryogenic probes.
Samples for NMR measurements typically contained 0.4–1 mM
protein in buffer containing 20 mM Tris-HCl7.0, 300 mM NaCl,
5 mM DTT, 1 mM EDTA, 0.01% NaN3, 0.2 mM AEBSF, and
10% D2O. The spectra were processed with NMRPipe [30] and
analyzed with XEASY[31]. Sequential resonance assignments for
eIF4AI-CTD and its complex with hippuristanol were obtained
from standard triple-resonance NMR experiments [HNCA,
HN(CA)CB, HN(CO)CA, HN(COCA)CB, HNCO, HN(CA)CO]
on uniformly
15N-/
13C-labeled samples with 70% deuteration.
15N-edited NOESY-HSQC and TOCSY-HSQC experiments
were recorded on uniformly
15N-labeled samples. Intermolecular
NOEs between eIF4AI-CTD and hippuristanol were measured
using uniformly
15N/
13C/
2H labelled CTD (52 mM) complexed
with 100 mM hippuristanol.
15N-dispersed NOESY spectra were
recorded in H2O, and exhibited intermolecular NOESY cross
peaks between peptide HN and hippuristanol in an otherwise
empty spectral region as described previously [32].
Homology modeling of the eIF4AI-CTD was previously
described [24]. The model of full-length eIF4AI was constructed
by manually superimposing the structure of human eIF4A-NTD
(PDB# 2G9N) and the homology model of eIF4AI-CTD with the
structure of eIF4AIII from the exon-junction complex (PDB#
2HYI) [22].
Recombinant DNA Constructs
Site-directed mutagenesis was performed using a PCR based
strategy. Oligonucleotides harboring the mutant sequence(s) were
used in amplification reactions with either upstream or down-
stream oligonucleotides spanning unique restriction sites (Table
SI). Following gel purification of PCR products, these were
combined and used in amplification reactions in the absence of
primer for 5 cycles, at which point primers targeting the ends of
the fragments were added and amplifications continued for 30
cycles. DNA fragments were cloned into expression plasmids using
convenient restrictions sites and all clones used in this study were
sequenced to ensure the absence of secondary undesired
mutations. The murine eIF4AI cDNA was subcloned from
pET3b/eIF4AI into pET15b using NdeI and BamHI restriction
enzymes [10]. The murine eIF4AII was excised from pACT2/
4AII with BamHI (which was rendered blunt by Klenow repair)
and XhoI, and inserted into the BamHI (blunt ended with
Klenow)/XhoI sites of pET28a. Human eIF4AIII mutants were
derived from pET-HTG-eIF4AIII [29] and subcloned into
pET28a (BamHI site).
Cloning strategies to generate the various mutants utilized in
this study were as follows: For pET15b/eIF4AI
IG, two PCR
products were produced using pET15b/eIF4AI as template and
the primer pairs: (i) DraIII Forward and IG Reverse and (ii) IG
Forward and BamHI Reverse (Table S1). Following gel purifica-
tion, the fragments were used to extend off of each during 5
rounds of PCR amplification, after which the primers DraIII
Forward and BamHI Reverse were used to amplify the full length
mutant. The product was digested with DraIII and BamHI and
inserted into pET15b/eIF4AI. For pET15b/eIF4AI
T, two PCR
products were produced using pET15b/eIF4AI as template and
the primer pairs: (i) DraIII Forward and T Reverse and (ii) T
Forward and BamHI Reverse (Table S1). The products were
combined and cloned as described for pET15b/eIF4AI
IG. For
pET15b/eIF4AI
IG/T, two PCR products were produced using
pET15b/eIF4AI
IG as template and the primer pairs: (i) DraIII
Forward and T Reverse and (ii) T Forward and BamHI Reverse
(Table S1). The products were combined and cloned as described
for pET15b/eIF4AI
IG. For pET15b/eIF4AI
IP/T, two PCR
products were produced using pET15b/eIF4AI as template and
the primer pairs: (i) DraIII Forward and IP Reverse and (ii) IP
Forward and BamHI Reverse (Table S1). The products were
combined and cloned as described for pET15b/eIF4AI
IG. Plasmid
pET15b/eIF4AI
IP was used as template for two PCR reactions,
using either (i) primers DraIII Forward and T Reverse and (ii) T
Forward and BamHI Reverse. The products were combined and
cloned as described for pET15b/eIF4AI
IG to generate pET15b/
eIF4AI
IP/T.
For pET15b/eIF4AI
Quad/IG/T, two PCR products were
produced using pET15b/eIF4AI
IG/T as template and the primer
pairs: (i) primers D265R/E268Kforward and 4A(1220–1238)(AS)
and (ii) D265R/E268Kreverse and pET15b Oligo (Table S1).
Following gel purification, the fragments were used to extend off of
each during 5 rounds of PCR amplification, after which the
primers pET15b Oligo and 4A(1220–1238)(AS) were used to
amplify the full length mutant. The product was digested with
NdeI and BamHI and inserted into the same sites in pET15b to
create pET15b/eIF4AI
RK/IG/T. An additional round of muta-
genesis was undertaken using this as template and the primer
pairs: (i) D296A/T298Kreverse and pET15b Oligo, and (ii)
D296A/T298Kforward and 4A(1220–1238)(AS) (Table S1).
Following gel purification, the fragments were used to extend off
of each other during 5 rounds of PCR amplification, after which
the primers pET15b Oligo and 4A(1220–1238)(AS) were used to
amplify the full length mutant. The product was digested with
NdeI and BamHI and inserted into the same sites in pET15b to
create pET15b/eIF4AI
Quad/IG/T. For pET15b/eIF4AI
Hel/IG/T,
two PCR products were produced using pET15b/eIF4AI
IG/T as
template and the primer pairs: (i) AIGforward and 4A(1220–
1238)(AS) and (ii) AIGreverse and pET15b Oligo (Table S1).
Following gel purification, the fragments were used to extend off of
each during 5 rounds of PCR amplification, after which the
primers pET15b Oligo and 4A(1220–1238)(AS) were used to
amplify the full length mutant. The product was digested with
NdeI and BamHI and inserted into the same sites in pET15b.
For pET28a/eIF4AII
IP/T, two PCR products were produced
using pET28a/eIF4AII as template and the primer pairs: (i) 4AII-
IP(S) and 4AII(1278–1258) and (ii) 4AII-NheI-NTD and 4AII-
IP(AS) (Table S1). Following gel purification, the fragments were
used to extend off of each during 5 rounds of PCR amplification,
after which the primers 4AII(1278-1258) and 4AII-NheI-NTD
were used to amplify the full length mutant. The product was
digested with NheI and XhoI and inserted into the same sites in
pET28a to generate pET28a/eIF4AII
IP. The T mutation was
introduced (Fig. S1) using pET28a/eIF4AII
IP as template and the
primer pairs: (i) 4AII-T(S) and 4AII(1278–1258) and (ii) 4AII-
NheI-NTD and 4AII-T(AS) (Table S1). Following gel purification,
the fragments were used to extend off of each during 5 rounds of
PCR amplification, after which the primers 4AII(1278–1258) and
4AII-NheI-NTD were used to amplify the full length mutant. The
product was digested with NheI and XhoI and inserted into the
same sites in pET28a.
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IP/T, two PCR products were produced
using pET28a/eIF4AII as template and the primer pairs: (i)
Primer D and Primer F and (ii) Primer E and Primer A (Table S1).
Following gel purification, the fragments were used to extend off of
each during 5 rounds of PCR amplification, after which the
primers Primer A and Primer D were used to amplify the full
length mutant. The product was digested with BamHI and
inserted into the same site in pET28a to generate pET28a/
eIF4AIII
IP. The T mutation was introduced (Fig. S1) using
pET28a/eIF4AIII
IP as template and the primer pairs: (i) Primer D
and Primer C and (ii Primer B and Primer A (Table S1). Following
gel purification, the fragments were used to extend off of each
during 5 rounds of PCR amplification, after which the primers
Primer A and Primer D were used to amplify the full length
mutant. The product was digested with BamHI and inserted into
the same site in pET28a. For pET28a/eIF4AIII
TLLQV, two PCR
products containing the TLLQV mutation were produced from
pET28a/eIF4AIII: one with the primers Primer D and
4AIII(TLLQV)AS and the other with 4AIII(TLLQV)S and
Primer A. Following gel purification, the fragments were used to
extend off of each during 5 rounds of PCR amplification, after
which the primers Primer A and Primer D were used to amplify
the full length mutant. The product was digested with BamHI and
inserted into the same site in pET28a.
Purification of Hippuristanol
Hippuristanol was extracted from the gorgonian I. hippuris as
previously described[20].
Recombinant Protein Expression and Purification
Recombinant His6-eIF4AI and His6-eIF4AII were expressed in
E. Coli BL21 (DE3) codon+. Bacteria were grown to an OD600 of
0.6 and induced with 1mM IPTG. Growth was continued an
additional 3h at 37uC. Wild-type and mutant eIF4AI and eIF4AII
proteins were resuspended in sonication buffer (20 mM Tris7.5,
10% glycerol, 0.1 mM EDTA, 200 mM KCl, 0.1% Triton X-100
and 3.4 mM b-mercaptoethanol). After sonication (9 pulses of
20 sec) and clarification by centrifugation (twice at 27,0006g for
30 min), the lysate was loaded on a Ni
++-NTA agarose (Qiagen)
column. The column was washed with 10 column volumes of wash
1 (20 mM Tris7.5, 10% glycerol, 0.1 mM EDTA, 800 mM KCl,
20 mM imidazole) and wash 2 (Wash 1 containing 300 mM KCl)
buffer, and the His6-tagged proteins were eluted (Wash 1 buffer
containing 300 mM KCl and 0.2 M imidazole), and dialyzed into
A100 buffer (20 mM Tris7.5, 10% glycerol, 0.1 mM EDTA,
100 mM KCl, 2 mM DTT). The protein was loaded onto a Q-
Sepharose Fast Flow (Amersham) column and eluted with a KCl
gradient A100 to A500 (20 mM Tris7.5, 10% glycerol, 0.1 mM
EDTA, 2 mM DTT ). The eluted protein was dialysed against
20 mM Tris7.5, 0.1 mM EDTA, and 10% glycerol.
Recombinant His6-eIF4AIII and mutants were purified through
aN i
++-NTA agarose (Qiagen) column as previously described
[33]. The eluent was diluted to a salt concentration of 100 mM
and passed through a Q-Sepharose Fast Flow (Amersham) column
and eIF4AIII collected in the flow through. His6-eIF4AIII was
stored in 20 mM Tris7.5, 0.1 mM EDTA, 100 mM KCl, 10 %
glycerol, and 2 mM DTT. His6-eIF4AIII
TLLQV was further
purified on a heparin-sepharose column.
The cDNA encoding hDDX52 [NM007010.2] was obtained
from Origene (Rockville, MD) and subcloned into the Not1 sites of
pET28a. The purification procedure was as described above for
eIF4AI using Ni
++-NTA agarose and Q-Sepharose. Recombinant
hDDX52 protein was stored in 20 mM Tris7.5, 10% glycerol,
0.1 mM EDTA, 2 mM DTT, 100mM KCl.
ATPase, RNA binding, and Helicase Assays
ATPase assays were performed as described by Lorsch and
Herschlag, using their ‘‘Condition B’’[34]. Briefly, 0.1 mgo r1mg
protein (indicated in figure legend) was incubated with 2.5 mM
poly (U) and 1 mM c-
32P-ATP (10 Ci/mmol) (0.01 mCi) at 25uC
(except where specifically indicated) and time points taken at the
indicated intervals by removing 2 mL aliquots and diluting into
2 mL of 25 mM EDTA. Inorganic phosphate and c-
32P-ATP were
separated by TLC as described previously [34]. Results were
quantitated using a Fujix BAS 2000 phosphoimager with a Fuji
imaging screen. The fraction of Pi at t=0 was typically 1–3% and
subtracted as background.
For Tif1/2p, 0.5 mg Tif1/2p and 1 mg yeast eIF4G (aa542-883)
was incubated with 12 nM 18S rRNA and 1 mM ATP at 25uC for
1h. The reaction was stopped with 50 mM EDTA and the
formation of free phosphate determined as ammonium molybdate
complex photometrically with malachite green (at A630) Calibra-
tion curves were prepared with increasing concentrations of
Na3PO4 (5–100 mM) (BioAssays Systems).
Chemically cross-linking was performed with 0.5–1 mg recom-
binant protein and oxidized
32P-labelled CAT mRNA
(,18,000 cpm/mg) in the presence of 0.9 mM ATP with 10 mM
hippuristanol or vehicle (DMSO) for 10 min at 30uC [20,35], after
which time sodium cyanoborohydride was added, and the
incubation continued overnight at 4uC. The samples were then
treated with RNAse A, separated on a 10% SDS-PAGE, and
visualized by autoradiography.
RNA helicase assays were performed as previously described
[7,36]. Briefly, 0.4 mM recombinant His6-eIF4AI or His6-eIF4AII
was incubated with 2 mM RNA-1/11 duplex in the presence of
1 mM ATP for 15 minutes at 35uC. Reactions were resolved on
native 12% polyacrylamide gels, which were dried and exposed to
X-Omat (Kodax) film at -70uC.
Rescue of hippuristanol-induced translation inhibition
The plasmid pKS/FF/HCV/Ren was linearized with BamHI
and transcribed with T3 RNA polymerase to generate FF/HCV/
Ren mRNA [20]. In vitro translations were performed in rabbit
reticulocyte lysates following the manufacturer’s instructions
(Promega). Extracts were programmed with FF/HCV/Ren
mRNA (8 mg/ml) and translations performed at a final concen-
tration of 135 mM KCl. eIF4A rescue experiments were
performed by the addition of 0.5 or 0.8 mg recombinant eIF4A
(0.9–1.4 mM) to vehicle- or hippuristanol -treated extracts. Firefly
luciferase activities were measured on a Berthold Lumat LB 9507
luminometer. Reactions performed in the presence of [
35S]methi-
onine were separated on a 10% SDS-polyacrylamide gel which
was treated with EN
3Hance, dried, and exposed to X-Omat
(Kodax) film at 270uC. For in vitro translation reactions in yeast,
wild type strain BY4741 was used to prepare an in vitro translation
extract and assays were performed as previously reported [37].
Translations in Xenopus oocytes were performed essentially as
previously described [38]. Briefly, collagenased Xenopus oocytes were
sorted and incubated for 4 h at 16uCi n5mMh i p p u r i s t a n o lo r
0.05% DMSO. Each oocyte was then injected with 50 nL of
0.94 mg/mL recombinant His6-eIF4AI or recombinant His6-
eIF4AI
IG/T or buffer alone immediately followed by 10 nL of
0.02 mM in vitro transcribed FF/HCV/Ren mRNA. Oocytes were
then incubated for 4h at room temperature in fresh compound
dilutions. Three oocytes were homogenized in 150 mL Passive Lysis
Buffer (Promega). The cell lysates were cleared by centrifugation at
140006g for 5 min. Ten microliters of the lysate was read per
sample using the Dual Luciferase Assay system (Promega). Values
were normalized to Renilla activity and the percent rescue
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divided by the average value of DMSO challenged samples.
Time resolved fluorescence resonance energy transfer (TR-
FRET). Recombinant His6-eIF4AI protein (20 nM ) and GST-
eIF4GI517-606 (40 nM) or GST-eIF4GI648–983 (200 nM) were
incubated with Eu-W1024 labeled anti-6xHis antibody (1 nM)
[Perkin Elmer] and anti-GST IgG antibody conjugated to
SureLight-Allophycocyanin (100 nM) [Perkin Elmer] in TR-FRET
buffer (20 mM Hepes7.4, 10 mM KCl, 1 mM DTT, 0.015% Tween
20, 1 mg/ml IgG). Reactions were performed at room temperature
for 3 hrs. FRET signal was monitored using an Analyst HT reader
(LJL Biosystems) [39]. Data collection using the ‘‘Criterion Host
v.2.0.1’’ software (LJL Biosystems) involved setting the Z height at
1 mm and utilizing 1 excitation filter (330/80) and 2 emission filters
(620/7.5and 665/7.5).A dichroic filter with a wavelength of 400 nm
was used. For the measurement at 620 nm we employed 100
readings per well, with 10 ms between reading, integration time of
1000 ms, a delay time of 200 ms and 1000 msi n t e g r a t i o nt i m ef o rt h e
fluorescence emission recording. The parameters for the
measurement at 665 nm were the same as for 620 nm, except for
an integration time of 150 ms and a delay time of 50 ms. Due to the
time delay, onlythe longer-lived FRET signal is detected, eliminating
short-lived background fluorescence. The 665/620 ratio was
calculated and normalized to the negative control reaction
(containing His6-eIF4EW73A which does not interact with eIF4G or
4E-BP) to yieldthe S/B ratio. The 665 nm emissions are due to APC
FRETand the620 nmemissionsare due toEu-W1024fluorescence.
Supporting Information
Table S1
Found at: doi:10.1371/journal.pone.0001583.s001 (0.05 MB
DOC)
Figure S1 Amino acid alignment of the hippuristanol binding
site among murine eIF4AI, murine eIF4AII, and human eIF4AIII
alleles used in this study. Direct protein-hippuristanol NOEs are
highlighted in yellow, whereas those within 5{Angstrom} are in
grey. Introduced amino acid changes are highlighted in red. The
position of the first and last amino acid of the motif is indicated.
Amino acids corresponding to the hippuristanol binding site in S.
cerevisiae Ded1p is also shown.
Found at: doi:10.1371/journal.pone.0001583.s002 (0.03 MB
DOC)
Figure S2 Amino acid alignment of the hippuristanol binding
site among DDX family members. Alignments shown are for
members of the murine (A) or human (B) DEAD box family
members. The Entrez Protein IDs are provided in parenthesis for
each member. Direct protein-hippuristanol NOEs are highlighted
in yellow, whereas those within 5{Angstrom} are in grey. The
position of the first and last amino acid of the motif in the protein
sequence is indicated.
Found at: doi:10.1371/journal.pone.0001583.s003 (0.07 MB
DOC)
Figure S3 RNA-dependent ATPase activity of eIF4AI
IG/T,
eIF4AI
IG, and eIF4AI
T mutant alleles. ATP hydrolysis was
monitored using 1 mg recombinant protein. Each value represents
the average of two measurements with the error of the mean
presented. [Note in this assay, the protein preparation was
different and not as active as the preparation used in Fig. 3A.]
Found at: doi:10.1371/journal.pone.0001583.s004 (10.00 MB
TIF)
Figure S4 Characterization of eIF4AI and eIF4AII hippurista-
nol-resistant mutants. (A) Crosslinking of recombinant proteins to
RNA in the presence of hippuristanol.
32P-labelled CAT RNA was
cross-linked to 0.5–1 mg of the indicated recombinant protein in
the presence or absence of hippuristanol, separated by SDS-
PAGE, and visualized by autoradiography. (B) The helicase
activities of the eIF4AI
IG/T and eIF4AII
IP/T mutants are resistant
to hippuristanol. Helicase assays were performed with recombi-
nant protein (0.4 mM) and duplexed RNA as described in the
Materials and Methods. Reactions were resolved on a native 12%
acrylamide gel, which was dried, and exposed to BioMax XAR
film (Kodak) film at 270uC. The position of migration of duplexed
(ds) and single-stranded (ss) RNA are denoted to the right.
Found at: doi:10.1371/journal.pone.0001583.s005 (5.78 MB TIF)
Figure S5 Characterization of eIF4A mutants. (A) RNA-depen-
dent ATPase activity of eIF4AI
Hel/IG/T and eIF4AI
Quad/IG/T
mutants. ATP hydrolysis was monitored using 1 mgr e c o m b i n a n t
protein. Each value represents the average of two measurements
with the error of the mean presented. In this experiment, the protein
preparationsweredifferentandnotasactiveasthepreparationsused
in Fig. 3A. (B) The helicase activity of eIF4AI
Hel/IG/T is impaired.
Recombinant protein (0.4 mM) was incubated with duplexed RNA
asdescribed inMaterialsand Methods.Reactionswereresolvedon a
native 12% acrylamide gel and visualized by autoradiography. The
migration of duplexed and ssRNA are determined by the incubation
of duplexed RNA alone at 35uC (lane 1) or boiling for 5 minutes
(lane 2), respectively. (C) Crosslinking of eIF4AI
Quad/IG/T and
eIF4AI
Hel/IG/T to RNA in the presence of hippuristanol.
32P-
labelled CAT RNA was cross-linked to 1 mg of the indicated
recombinant protein in the presence or absence of hippuristanol,
separated by SDS-PAGE, and visualized by autoradiography. (D)
Helicase activity of eIF4AI
Quad/IG/T is not impaired and resistant to
hippuristanol. Helicase assays were performed with recombinant
protein (0.4 mM) and duplexed RNA as described in the Materials
and Methods. Reactions were resolved on a native 12% acrylamide
gel,whichwasdried,andexposed toBioMaxXARfilm(Kodak)film
at 270uC. The position of migration of duplexed (ds) and single-
stranded (ss) RNA are denoted to the right.
Found at: doi:10.1371/journal.pone.0001583.s006 (4.08 MB TIF)
Figure S6 The interaction of eIF4AI
Quad/IG/T with eIF4GI is
impaired. (A) Schematic representation of the various functional
domains of eIF4GI. Protein and RNA binding sites on eIF4GI are
indicated. The numbers below eIF4GI refer to the amino acid
location of each binding site. A schematic of the recombinant
eIF4GI fragments utilized and the regions they span are shown in
grey boxes. (B) TR-FRET analysis of the interaction between
eIF4AI, eIF4AI
IG/T, eIF4AI
Quad/IG/T with eIF4GI fragments.
GST-eIF4GI fragments were incubated with recombinant His6-
eIF4AI protein, as well as with Eu-W1024 labeled anti-6xHis
antibody and anti-GST IgG antibody conjugated to SureLight-
Allophycocyanin. The FRET signal (expressed as the signal to
background ratio (S/B)) was monitored on an Analyst reader (LJL
Biosystems) and represents the average of 4 experiments with the
standard error of the mean shown. The signal obtained with
eIF4AI and eIF4G517-606 was equivalent to the background signal
(S/B=1).
Found at: doi:10.1371/journal.pone.0001583.s007 (4.39 MB TIF)
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